Aldeyra Therapeutics Inc. (ALDX)

4.71
NASDAQ : Health Technology
Prev Close 4.98
Day Low/High 4.64 / 5.12
52 Wk Low/High 4.75 / 16.70
Avg Volume 232.20K
Exchange NASDAQ
Shares Outstanding 27.58M
Market Cap 137.34M
EPS -1.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Aldeyra Therapeutics Becomes Oversold (ALDX)

Aldeyra Therapeutics Becomes Oversold (ALDX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Relative Strength Alert For Aldeyra Therapeutics

Relative Strength Alert For Aldeyra Therapeutics

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Aldeyra Therapeutics Announces Results From The SOLACE Trial In Noninfectious Anterior Uveitis

Aldeyra Therapeutics Announces Results From The SOLACE Trial In Noninfectious Anterior Uveitis

Aldeyra Therapeutics, Inc. ( Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced results from the...

Aldeyra Therapeutics Schedules Webcast And Conference Call To Announce Top-Line Results From The SOLACE Trial In Noninfectious Anterior Uveitis

Aldeyra Therapeutics Schedules Webcast And Conference Call To Announce Top-Line Results From The SOLACE Trial In Noninfectious Anterior Uveitis

Aldeyra Therapeutics, Inc. ( Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced it will hold a webcast and...

Aldeyra Therapeutics To Participate In The Jefferies 2019 Global Healthcare Conference

Aldeyra Therapeutics To Participate In The Jefferies 2019 Global Healthcare Conference

LEXINGTON, Mass., May 30, 2019 /PRNewswire/ -- Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics Is Now Oversold (ALDX)

Aldeyra Therapeutics Is Now Oversold (ALDX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Aldeyra Therapeutics Announces First Quarter 2019 Financial Results And Provides Corporate Update

Aldeyra Therapeutics Announces First Quarter 2019 Financial Results And Provides Corporate Update

- Reported Positive Results from Phase 3 ALLEVIATE Trial in Allergic Conjunctivitis

Aldeyra Therapeutics To Report First Quarter 2019 Financial Results And Host Conference Call On Thursday, May 9, 2019

Aldeyra Therapeutics To Report First Quarter 2019 Financial Results And Host Conference Call On Thursday, May 9, 2019

LEXINGTON, Mass., May 2, 2019 /PRNewswire/ -- Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics Announces Last Patient Dosed In The SOLACE Phase 3 Clinical Trial

Aldeyra Therapeutics Announces Last Patient Dosed In The SOLACE Phase 3 Clinical Trial

LEXINGTON, Mass., April 30, 2019 /PRNewswire/ --  Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics (ALDX) Shares Cross Above 200 DMA

Aldeyra Therapeutics (ALDX) Shares Cross Above 200 DMA

In trading on Wednesday, shares of Aldeyra Therapeutics Inc crossed above their 200 day moving average of $8.92, changing hands as high as $8.94 per share. Aldeyra Therapeutics Inc shares are currently trading up about 3.7% on the day.

Aldeyra Therapeutics Announces First Patient Enrolled In The RENEW Phase 3 Clinical Trial For Dry Eye Disease

Aldeyra Therapeutics Announces First Patient Enrolled In The RENEW Phase 3 Clinical Trial For Dry Eye Disease

LEXINGTON, Mass., April 2, 2019 /PRNewswire/ -- Aldeyra Therapeutics, Inc.

Future Brightens for 2 Small Biotech Stocks

Future Brightens for 2 Small Biotech Stocks

The biotech sector isn't for the faint of heart, but these two companies issued promising news this week.

Aldeyra Therapeutics Announces Positive Top-Line Results From The Phase 3 ALLEVIATE Trial In Patients With Allergic Conjunctivitis

Aldeyra Therapeutics Announces Positive Top-Line Results From The Phase 3 ALLEVIATE Trial In Patients With Allergic Conjunctivitis

- Primary endpoint of ocular itch score area under the curve achieved for both tested reproxalap concentrations

Aldeyra Therapeutics Schedules Webcast And Conference Call To Announce Top-Line Results From The Phase 3 ALLEVIATE Trial In Allergic Conjunctivitis

Aldeyra Therapeutics Schedules Webcast And Conference Call To Announce Top-Line Results From The Phase 3 ALLEVIATE Trial In Allergic Conjunctivitis

LEXINGTON, Mass., March 25, 2019 /PRNewswire/ -- Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics Shares Cross Above 200 DMA

Aldeyra Therapeutics Shares Cross Above 200 DMA

In trading on Tuesday, shares of Aldeyra Therapeutics Inc crossed above their 200 day moving average of $8.91, changing hands as high as $9.00 per share. Aldeyra Therapeutics Inc shares are currently trading up about 11.4% on the day.

Aldeyra Therapeutics Announces Year-End 2018 Financial Results

Aldeyra Therapeutics Announces Year-End 2018 Financial Results

- Results from the ALLEVIATE Phase 3 Clinical Trial in Allergic Conjunctivitis Expected in Early 2019

Aldeyra Therapeutics To Report Fourth Quarter And Full Year 2018 Financial Results And Host Conference Call On Friday, March 8, 2019

Aldeyra Therapeutics To Report Fourth Quarter And Full Year 2018 Financial Results And Host Conference Call On Friday, March 8, 2019

LEXINGTON, Mass., March 1, 2019 /PRNewswire/ -- Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics Provides Update On Ophthalmic Programs At 2019 Research & Development Day

Aldeyra Therapeutics Provides Update On Ophthalmic Programs At 2019 Research & Development Day

Phase 3 Results from ALLEVIATE Trial in Allergic Conjunctivitis Expected in Early 2019

Aldeyra Therapeutics (ALDX) Shares Cross Above 200 DMA

Aldeyra Therapeutics (ALDX) Shares Cross Above 200 DMA

In trading on Thursday, shares of Aldeyra Therapeutics Inc crossed above their 200 day moving average of $8.88, changing hands as high as $9.28 per share. Aldeyra Therapeutics Inc shares are currently trading up about 1.5% on the day.

Notable Thursday Option Activity: ALDX, WYNN, DECK

Notable Thursday Option Activity: ALDX, WYNN, DECK

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Aldeyra Therapeutics Inc , where a total volume of 1,768 contracts has been traded thus far today, a contract volume which is representative of approximately 176,800 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 75.9% of ALDX's average daily trading volume over the past month, of 233,055 shares.

Aldeyra Therapeutics Is Now Oversold (ALDX)

Aldeyra Therapeutics Is Now Oversold (ALDX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Aldeyra Therapeutics Is Now Oversold (ALDX)

Aldeyra Therapeutics Is Now Oversold (ALDX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Oversold Conditions For Aldeyra Therapeutics (ALDX)

Oversold Conditions For Aldeyra Therapeutics (ALDX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

2 Small Biopharmas With Case of 'Hiccups'

2 Small Biopharmas With Case of 'Hiccups'

Insiders are taking advantage of opportunities in Intra-Cellular Therapies and Aldeyra.

Aldeyra Leaps on Data for Dry Eye Disease Treatment - Biotech Movers

Aldeyra Leaps on Data for Dry Eye Disease Treatment - Biotech Movers

The Lexington, Mass.-based company unveiled results from its Phase 2a study of ADX-102 in dry eye disease. Other biotech movers in premarket trading on Sept. 12 include Sage Therapeutics and Intercept Pharmaceuticals.